MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Holdings in Privia Health Group, Inc. (NASDAQ:PRVA)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. decreased its stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 9.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 115,050 shares of the company's stock after selling 11,387 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned about 0.10% of Privia Health Group worth $2,249,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in PRVA. First Horizon Advisors Inc. lifted its position in Privia Health Group by 53.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock worth $35,000 after buying an additional 632 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in Privia Health Group by 7,833.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock worth $47,000 after acquiring an additional 2,350 shares during the last quarter. Quadrant Capital Group LLC increased its stake in Privia Health Group by 11.8% during the fourth quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock worth $95,000 after acquiring an additional 511 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Privia Health Group by 185.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,999 shares of the company's stock worth $98,000 after acquiring an additional 3,249 shares during the last quarter. Finally, KBC Group NV increased its stake in Privia Health Group by 48.1% during the fourth quarter. KBC Group NV now owns 5,012 shares of the company's stock worth $98,000 after acquiring an additional 1,627 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company's stock.

Wall Street Analysts Forecast Growth

PRVA has been the subject of several recent analyst reports. Robert W. Baird raised their target price on Privia Health Group from $24.00 to $26.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 15th. Canaccord Genuity Group raised their target price on Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Barclays raised their target price on Privia Health Group from $23.00 to $24.00 and gave the stock an "equal weight" rating in a research note on Tuesday. Piper Sandler lifted their price objective on Privia Health Group from $25.00 to $40.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $29.00 price objective on shares of Privia Health Group in a research note on Monday, April 28th. One research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $27.46.

Privia Health Group Trading Up 2.0%

PRVA traded up $0.46 on Tuesday, hitting $23.32. 688,994 shares of the company were exchanged, compared to its average volume of 738,725. Privia Health Group, Inc. has a twelve month low of $16.37 and a twelve month high of $26.09. The company has a market cap of $2.84 billion, a price-to-earnings ratio of 233.22, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87. The firm has a 50-day moving average price of $23.37 and a two-hundred day moving average price of $22.71.

Insider Buying and Selling

In related news, CFO David Mountcastle sold 5,630 shares of the business's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total transaction of $125,999.40. Following the completion of the transaction, the chief financial officer now directly owns 179,676 shares of the company's stock, valued at $4,021,148.88. The trade was a 3.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Parth Mehrotra sold 13,773 shares of the business's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $24.99, for a total value of $344,187.27. Following the transaction, the chief executive officer now directly owns 423,143 shares of the company's stock, valued at $10,574,343.57. The trade was a 3.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,579 shares of company stock valued at $1,226,367 in the last three months. 10.70% of the stock is owned by corporate insiders.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.